[{"id":"d1bc1259-71d0-45e4-a4ce-99f4232d61c4","acronym":"AZURE","url":"https://clinicaltrials.gov/study/NCT05609942","created_at":"2023-04-03T15:02:58.943Z","updated_at":"2025-02-25T14:41:39.851Z","phase":"Phase 1","brief_title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","source_id_and_acronym":"NCT05609942 - AZURE","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • elenestinib (BLU-263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 01/14/2025","primary_completion_date":" 01/14/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-14"},{"id":"1d571185-66c3-4224-a385-8f3e4c2f1022","acronym":"PATHFINDER","url":"https://clinicaltrials.gov/study/NCT03580655","created_at":"2021-01-18T17:36:58.229Z","updated_at":"2024-07-02T16:35:41.207Z","phase":"Phase 2","brief_title":"(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis","source_id_and_acronym":"NCT03580655 - PATHFINDER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" TMB • KIT","pipe":" | ","alterations":" KIT mutation • KIT D816V","tags":["TMB • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-08-02"},{"id":"0b135f3f-be0a-43ad-bf86-0ed39a7b1f3a","acronym":"EXPLORER","url":"https://clinicaltrials.gov/study/NCT02561988","created_at":"2021-01-18T12:24:19.958Z","updated_at":"2024-07-02T16:35:53.073Z","phase":"Phase 1","brief_title":"(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies","source_id_and_acronym":"NCT02561988 - EXPLORER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT D816V","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 10/05/2022","primary_completion_date":" 10/05/2022","study_txt":" Completion: 01/19/2023","study_completion_date":" 01/19/2023","last_update_posted":"2023-03-17"},{"id":"26ae9c5b-9e27-474b-b2b2-7da22d271c95","acronym":"","url":"https://clinicaltrials.gov/study/NCT01866839","created_at":"2021-01-18T08:21:07.646Z","updated_at":"2024-07-02T16:36:42.947Z","phase":"Phase 1/2","brief_title":"Preventing Stem Cell Transplant Complications With a Blood Separator Machine","source_id_and_acronym":"NCT01866839","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" KIT • PDGFRA • FIP1L1","pipe":"","alterations":" ","tags":["KIT • PDGFRA • FIP1L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/29/2013","start_date":" 05/29/2013","primary_txt":" Primary completion: 05/23/2018","primary_completion_date":" 05/23/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2020-07-21"},{"id":"5ff22ee6-6c95-4b3e-80e2-eb69bcdf6c52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01199562","created_at":"2021-01-18T04:48:21.624Z","updated_at":"2025-02-25T16:23:31.204Z","phase":"","brief_title":"Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","source_id_and_acronym":"NCT01199562","lead_sponsor":"City of Hope Medical Center","biomarkers":" NCAM1 • LAMP2","pipe":"","alterations":" ","tags":["NCAM1 • LAMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Valcyte (valganciclovir)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2019-04-25"},{"id":"656a1b45-0caf-4724-949d-11c7eaee126c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01807598","created_at":"2021-01-18T08:00:54.554Z","updated_at":"2024-07-02T16:37:03.399Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia","source_id_and_acronym":"NCT01807598","lead_sponsor":"Jason Robert Gotlib","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2019-01-29"},{"id":"6bd33a9c-f4ee-4a92-aa92-daf2c3b67d77","acronym":"","url":"https://clinicaltrials.gov/study/NCT00233454","created_at":"2021-01-18T00:47:26.549Z","updated_at":"2025-02-25T15:47:35.440Z","phase":"Phase 2","brief_title":"Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia","source_id_and_acronym":"NCT00233454","lead_sponsor":"Jason Robert Gotlib","biomarkers":" KIT • PDGFRA • FIP1L1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • FIP1L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 06/18/2010","primary_completion_date":" 06/18/2010","study_txt":" Completion: 04/16/2011","study_completion_date":" 04/16/2011","last_update_posted":"2018-09-20"},{"id":"669d0c34-2ea1-4225-bed3-4c850be55e4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02226861","created_at":"2021-01-18T10:26:32.104Z","updated_at":"2024-07-02T16:37:09.250Z","phase":"Phase 1","brief_title":"Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02226861","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" KIT • PDGFRA • FIP1L1 • IL2","pipe":"","alterations":" ","tags":["KIT • PDGFRA • FIP1L1 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 08/26/2014","start_date":" 08/26/2014","primary_txt":" Primary completion: 05/23/2018","primary_completion_date":" 05/23/2018","study_txt":" Completion: 06/27/2018","study_completion_date":" 06/27/2018","last_update_posted":"2018-07-05"},{"id":"4de7f334-1be6-452a-878d-44edcf23018e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00118352","created_at":"2021-01-18T00:23:57.200Z","updated_at":"2024-07-02T16:37:21.595Z","phase":"Phase 2","brief_title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00118352","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/26/2015","study_completion_date":" 05/26/2015","last_update_posted":"2017-05-30"},{"id":"7778f5d4-6d5a-4b6e-8cc1-927aa852f355","acronym":"","url":"https://clinicaltrials.gov/study/NCT00112593","created_at":"2021-01-18T00:22:32.319Z","updated_at":"2025-02-25T16:21:57.663Z","phase":"","brief_title":"Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer","source_id_and_acronym":"NCT00112593","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 11/01/1999","start_date":" 11/01/1999","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":"","study_completion_date":"","last_update_posted":"2017-05-24"}]